New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 14, 2013
11:01 EDTKBR, NVS, AFFY, NRF, ESIHigh option volume stocks: NVS ESI AFFY KBR NRF
News For NVS;ESI;AFFY;KBR;NRF From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 19, 2014
06:53 EDTESIWhitie House unveils college ratings blueprint, Reuters says
Subscribe for More Information
December 17, 2014
15:09 EDTNVSNovartis unit gets FDA approval for swimmerís ear treatment
Subscribe for More Information
11:01 EDTKBRBalyasny Asset reports 5.57% passive stake in KBR
07:29 EDTNVSFDA PDUFA Date for Novartis Bexsero is December 17, 2014
Subscribe for More Information
December 16, 2014
08:47 EDTNVSHemispherx Ampligen provides anti-tumor activity
Subscribe for More Information
07:06 EDTNVSBioLineRx and Novartis enter into strategic collaboration agreement
Subscribe for More Information
05:48 EDTNVSNovartis gains FDA approval for Signifor LAR
Subscribe for More Information
December 12, 2014
08:36 EDTNVSNovartis reports BOLERO-1 trial did not meet primary objective
Subscribe for More Information
05:31 EDTNVSNovartis reports Cosentyx 'superior' in head-to-head psoriasis study
Subscribe for More Information
December 11, 2014
09:24 EDTKBRKBR says looks to reduce annual operating expenses by $200M by 2016
Subscribe for More Information
08:08 EDTKBRKBR sees pre-tax charge of $800M-$1B related to restructuring
Effective December 31, 2014, KBR, Inc. will be reorganized into three new businesses. The actions are expected to strengthen KBR's balance sheet by addressing and exiting under-performing and non-strategic businesses. The company expects to realize annual operating cost savings of $200M by 2016, but anticipate taking a pre-tax charge ranging from $800M-$1B, the majority of which will be non-cash. The company currently has a cash balance of approximately $1B and has received approval from its lenders to amend its credit facility for the impact of the anticipated charge.
08:06 EDTKBRKBR to divest or exit several non-strategic businesses
KBR announced the results of a major Strategic Review which will see the company become a more streamlined, empowered and accountable global organization. Effective December 31, 2014, KBR, Inc. will be reorganized into three new businesses that will focus on core strengths in consulting, technology, engineering and construction and government services: Technology & Consulting combines all proprietary KBR technologies, knowledge-based services and KBR companies Granherne, Energo and GVA under one customer-facing global business to provide licensed technologies and consulting services to the oil and gas value chain, for wellhead to crude refining and to specialty chemicals production. In addition to sharing many of the same customers, these businesses share their approach of early and continuous involvement to deliver the most optimal solution to meet the customer's objectives through early planning and scope definition, advanced technologies and project lifetime support. This focus allows early customer engagement and continuity through to full project delivery; Engineering & Construction is KBR's project delivery business. It will leverage our operational and technical excellence as a global provider of engineering, procurement, construction, commissioning and maintenance for oil and gas, refining, petrochemicals, chemicals and industrial customers. Through a regional structure, E&C has been designed to be closer to its customers and capable to execute global project delivery on a consistent basis throughout the world; Government Services will focus on long-term services contracts with annuity streams particularly for the United Kingdom, Australian and United States governments. KBR functions at a corporate level will be streamlined. This will result in a lean corporate office with responsibility for strategy and governance. As a result of this Strategic Review, KBR will be divesting or exiting the following non-strategic businesses as it works to streamline global operations and drive efficiency with a goal of reducing annual operating costs of at least $200M by 2016: Fixed Price EPC Power; Fixed Price EPC Infrastructure and U.S. Minerals; Building Group; and Fixed Price, stand-alone Construction. In addition, options for Canadian module fabrication and U.S. military deployed operations support businesses are still under consideration.
December 8, 2014
13:07 EDTNVSNovartis announces data from Jakavi trial
Novartis (NVS) announced data from the largest clinical trial of myelofibrosis patients treated with Jakavi, supporting the safety profile and efficacy benefit as measured in primary and secondary endpoints respectively. In an analysis of 1,144 patients treated with Jakavi to date in this ongoing expanded access study, 69% of patients achieved >50% reduction in spleen size from baseline and patients also experienced a clinically meaningful improvement in myelofibrosis symptom score, important treatment goals for patients with myelofibrosis. Findings from the study were presented at the 56th Annual Meeting of the American Society of Hematology in San Francisco, California. Novartis research and development efforts, in collaboration with Incyte Corporation (INCY), include early-phase and post-marketing studies in myelofibrosis and other myeloproliferative neoplasms. More than 50 abstracts on ruxolitinib are being presented at ASH, including three oral presentations exploring combinations of ruxolitinib with various investigational compounds, evaluating the possibility of simultaneously targeting multiple cancer pathways that may be involved in the pathogenesis of myelofibrosis. The JUMP study is a Phase IIIb, expanded-access trial for countries with no access to Jakavi outside of a clinical trial. The open-label, multicenter study analyzed 1,144 enrolled myelofibrosis patients who received daily starting doses of either 5 mg, 15 mg or 20 mg of Jakavi twice daily based on platelet counts at baseline. The primary endpoint is assessment of safety and tolerability of Jakavi. Overall, the safety and efficacy profile of Jakavi was consistent with previous studies.
13:05 EDTNVSNovartis reports six-year results from Phase III ENESTnd study
Subscribe for More Information
12:00 EDTKBRKBR to host investor meeting
Investor meeting to be held in New York on December 11 at 9 am. Webcast Link
11:30 EDTNVSLeerink generics pharmaceutical analyst holds analyst/industry conference call
Subscribe for More Information
05:42 EDTNVSSandoz Phase III data shows filgrastim has similar safety, efficacy as NEUPOGEN
Sandoz, a Novartis (NVS) company, announced Phase III data that demonstrated similarity of its investigational biosimilar filgrastim compared to the US-licensed reference product, Amgen's (AMGN) NEUPOGEN in the prevention of severe neutropenia in patients with breast cancer receiving neoadjuvant myelosuppressive chemotherapy. The study also showed that repeated switching at each cycle between the investigational biosimilar and the originator filgrastim showed no impact on efficacy, safety or immunogenicity. The PIONEER study was a Phase III study designed to compare the efficacy and safety of the investigational biosimilar and the reference product with respect to mean duration of severe neutropenia following Cycle 1 chemotherapy. PIONEER was a randomized, double-blind, four-group, multi-center non-inferiority trial conducted at 27 centers. The trial randomized 218 breast cancer patients receiving neoadjuvant myelosuppressive chemotherapy.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use